Mirati Therapeutics Short Interest Ratio and Short Volume

Mirati Therapeutics (NASDAQ:MRTX) Short Interest Frequently Asked Questions

What is Mirati Therapeutics' current short interest?

Short interest is the volume of Mirati Therapeutics shares that have been sold short but have not yet been closed out or covered. As of November 15th, investors have sold 3,220,000 shares of MRTX short. 6.76% of Mirati Therapeutics' shares are currently sold short. Learn More on Mirati Therapeutics' current short interest.

What is a good short interest ratio for Mirati Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Mirati Therapeutics currently has a short interest ratio of 6.0. Learn More on a good short interest ratio for Mirati Therapeutics

Which institutional investors are shorting Mirati Therapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Mirati Therapeutics: Centiva Capital LP, Jane Street Group LLC, Millennium Management LLC, Citadel Advisors LLC, Centiva Capital LP, CSS LLC IL, Caption Management LLC, Wolverine Trading LLC, and Barclays PLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Mirati Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.76% of Mirati Therapeutics' floating shares are currently sold short.

Is Mirati Therapeutics' short interest increasing or decreasing?

Mirati Therapeutics saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 3,220,000 shares, a decline of 16.6% from the previous total of 3,860,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Mirati Therapeutics' float size?

Mirati Therapeutics currently has issued a total of 51,820,000 shares. Some of Mirati Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Mirati Therapeutics currently has a public float of 47,660,000 shares.

How does Mirati Therapeutics' short interest compare to its competitors?

6.76% of Mirati Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Mirati Therapeutics: Genmab A/S (0.00%), Genmab A/S (0.00%), Shiseido Company, Limited (0.00%), Royalty Pharma plc (1.94%), Horizon Therapeutics Public Limited (2.70%), UCB SA (0.00%), Alnylam Pharmaceuticals, Inc. (0.00%), Catalent, Inc. (0.00%), BioMarin Pharmaceutical Inc. (5.57%), and Viatris Inc. (0.00%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Advanced Micro Devices, Inc. ($11.06 billion), S&P Global Inc. ($8.74 billion), Charter Communications, Inc. ($5.66 billion), Canadian Pacific Railway Limited ($5.43 billion), Wayfair Inc. ($4.23 billion), Palo Alto Networks, Inc. ($3.46 billion), DoorDash, Inc. ($3.41 billion), Teladoc Health, Inc. ($2.84 billion), Etsy, Inc. ($2.76 billion), and Zscaler, Inc. ($2.62 billion). View all of the most shorted stocks.

What does it mean to sell short Mirati Therapeutics stock?

Short selling MRTX is an investing strategy that aims to generate trading profit from Mirati Therapeutics as its price is falling. Mirati Therapeutics' stock is trading down $4.71 today. To short Mirati Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Mirati Therapeutics will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Mirati Therapeutics?

A short squeeze for Mirati Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MRTX, which in turn drives the price of the stock up even further.

How often is Mirati Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MRTX, twice per month. The most recent reporting period available is November, 15 2021.